Angiosarcoma of the Liver
Angiosarcoma of the liver is a rare and aggressive primary cancer that arises from the cells lining the small blood vessels within the liver. It is much less common than other primary liver cancers such as hepatocellular carcinoma and cholangiocarcinoma but is one of the most common sarcomas of the liver. Hepatic angiosarcoma has been associated with specific exposures—such as vinyl chloride, thorium dioxide, and arsenic—although most cases today have no identifiable cause. Imaging, biopsy, and specialized care are central to diagnosis, and treatment is highly individualized and best provided in centers with expertise in sarcomas and hepatobiliary cancer.
What is it?
The liver contains a dense network of small blood vessels that bring blood to the liver tissue and return it toward the heart. The cells that line the inside of these vessels (endothelial cells) and their surrounding tissues can—rarely—give rise to a cancer called angiosarcoma. Angiosarcoma of the liver is an aggressive sarcoma in which abnormal vascular cells form a malignant tumor that can grow rapidly, often forms multiple lesions throughout the liver, and has a tendency to bleed.
Hepatic angiosarcoma is rare. It is much less common than the most frequent primary liver cancer (hepatocellular carcinoma) or cholangiocarcinoma, but it is one of the most common sarcomas of the liver. Most cases occur in adults, particularly older adults, and the disease is more common in men.
A small but historically important subset of hepatic angiosarcomas has been linked to specific environmental exposures. Vinyl chloride monomer—used in the production of polyvinyl chloride (PVC) plastics—has been a well-documented occupational risk factor, particularly with high-level exposures in earlier decades; modern industrial standards have substantially reduced this risk. Thorium dioxide (Thorotrast), a radioactive contrast agent used in medical imaging in the mid-20th century, has been associated with hepatic angiosarcoma decades after exposure but is no longer in use. Arsenic exposure and certain other industrial chemicals have also been implicated. Despite these recognized exposures, most patients diagnosed with hepatic angiosarcoma today have no identifiable cause. Underlying liver disease, immunosuppression, and certain genetic conditions are occasional contributors. Angiosarcoma is distinct from infantile hepatic hemangioendothelioma and from benign hepatic hemangiomas, which have very different biology and outcomes.
Symptoms of hepatic angiosarcoma can be vague or absent early on and often become apparent only as the tumor enlarges. Common symptoms include upper right abdominal pain or fullness, fatigue, unintentional weight loss, loss of appetite, nausea, and a general sense of being unwell. Jaundice, abdominal swelling, fever, and anemia (sometimes related to bleeding within the tumor) may also occur. A particularly important feature is the tendency for hepatic angiosarcomas to bleed; in some patients, the disease is identified when a tumor ruptures, producing sudden severe abdominal pain, lightheadedness, and signs of shock—a surgical emergency.
Diagnosis combines clinical assessment, laboratory tests, and imaging, followed by tissue confirmation with expert pathology review. Blood tests may show abnormal liver function, anemia, or low platelet counts. Tumor markers used for other liver cancers (such as alpha-fetoprotein and CA 19-9) are generally not elevated in angiosarcoma. Imaging typically begins with ultrasound, which may identify one or more liver lesions and bleeding. CT with contrast and MRI with contrast provide detailed characterization and staging information; hepatic angiosarcomas can have varied appearances on imaging, often with prominent vascular features, areas of necrosis, and signs of bleeding. PET/CT can be helpful in select cases for assessing systemic spread. Tissue confirmation—through image-guided biopsy or surgical sampling—is generally required, with care taken because the tumor’s vascular nature increases bleeding risk. Specialized immunohistochemistry and molecular studies are used by expert pathologists to confirm the diagnosis and distinguish angiosarcoma from other liver lesions, including benign vascular conditions, hepatic epithelioid hemangioendothelioma, and other cancers.
Important to Know
Treatment of hepatic angiosarcoma is highly individualized and is best delivered in centers with expertise in sarcomas and hepatobiliary cancers. Because the disease is rare and aggressive, care typically involves a multidisciplinary team that may include hepatobiliary surgeons, medical and radiation oncologists with sarcoma expertise, interventional radiologists, hepatologists, pathologists, palliative care specialists, and others.
For carefully selected patients with localized disease, surgical resection offers the best chance for long-term control. However, because hepatic angiosarcoma often presents with multiple lesions throughout the liver, advanced disease, or rapid growth, fewer patients are candidates for surgery compared with other primary liver cancers. Liver transplantation has been considered in selected cases, although outcomes have generally been less favorable than in other indications and the role of transplantation remains limited.
Systemic therapy is the mainstay of treatment for advanced or unresectable disease. Standard chemotherapy regimens used in soft tissue sarcomas—such as doxorubicin-based regimens, often in combination with other agents—are commonly used. Newer options, including targeted therapies that influence vascular signaling pathways and immunotherapy, are increasingly being explored. Because the disease is rare, clinical trial participation can be especially important and is offered when available.
Radiation therapy is used in selected cases, often for symptom control or in combination with other treatments. Locoregional approaches—such as transarterial chemoembolization, radioembolization, and ablation—may be considered in select patients to control specific lesions or manage bleeding.
Management of complications is essential. Acute bleeding from a hepatic angiosarcoma is a life-threatening emergency and may require interventional radiology procedures (such as transarterial embolization) or emergency surgery. Supportive care, transfusions, and management of liver dysfunction may also be needed.
Supportive and palliative care play important roles throughout the course of disease. This includes pain management, nutritional support, treatment of fatigue, management of psychological wellbeing, and family-centered care planning. Early integration of palliative care—even alongside active cancer treatment—is associated with improved quality of life.
Because hepatic angiosarcoma is so rare and outcomes are challenging, referral to specialized centers, accurate pathology review, and consideration of clinical trials are particularly important. Patients with prior environmental or occupational exposures relevant to this cancer may benefit from informed discussion about their history with their care team.
Red flag symptoms include sudden severe upper abdominal pain, lightheadedness or fainting, rapid heart rate, cool clammy skin or signs of shock, severe vomiting with abdominal pain, severe jaundice, signs of gastrointestinal bleeding, rapidly growing abdominal mass, or significant unintentional weight loss with fatigue. These warrant prompt or urgent medical evaluation, as they may indicate complications such as tumor rupture or progression of disease.